bone and fat immunity Flashcards
M-CSF
released by Osteoblasts and promotes Osteaoclasts survival and proliferation
where is RANK expressed
Pre-osteoclasts and osteoclast
OPG (Osteoprotegerin)
mainly produced by OB (but also stromal and immune cells), it acts as a decoy receptor binding RANKL and preventing its effects on RANK
RANKL
key cytokine that directs terminal differentiation of preosteoclasts to osteoclast thereby driving bone resorption
determining bone loss vs increase
mainly the balance between RANKL-RANK-OPG. Any condition that alters this ratio will be associated with bone PATHOLOGY
Osteoblast secretes
M-CSF, OPG, RANKL
RANKL is induced by
proinflammatory cytokines: IL 1, 6, 8, and INF-a and especially IL 17
RANKL is inhibited by
anti-inflammatory cytokines like IL 4, 10 (inhibit OC)
Th1 response
INF-g and activated macrophages result in pro-clastogenic and bone resorption
Th17
potent OC activators. IL 17 both directly promotes OC differentiation and proliferation and stimulates OBs to make more RANKL
normal Th1/Th2 balance
suppresses Th17 via either IL-4 or INF-g suppressing IL-17 production- good
osteoblast come from
osteochondral precursors
osteoclast come from
monocyte precursors (retain some macrophage proteries)
Rheumatoid Arthritis
IL-23-stimulus unknown- appears in high levels in synovium of a joint
Th17 cells infiltrate the synovium
IL-17 activates neighboring OC and they proliferate
The RANK/RANKL/OPG balance is pro-bone loss and causes bony erosions and loss of joint function
Osteoporosis and menopause
Premenopausal state: estrogen promotes normal OB & OC function
Post menopausal state: OPG/RANKL balance is altered
High levels of RANKL cause net increase in OC activity
Blocking RANKL with a monoclonal antibody can lead to decreased bone loss